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After propensity score matching (181 patients per group), 3-year survival was
significantly higher in patients treated with IS.
Conclusions: In a real-world setting of patients admitted with NSTEMI,
the use of IS during the initial hospital stay is an independent predictor of
improved 3-year survival, regardless of age.
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Objectives Coronary artery spasm is an important physiopathological
mechanism in some forms of myocardial ischemic disease. Increased levels of
inflammatory markers and mean platelet volume (MPV) are associated with
increased risk thromboembolism, but the relationship between these parame-
ters and coronary artery spasm is unclear.
Methods During coronary angiography, iv methylergometrin was injected
to 345 patients with chest pain and normal coronary angiograms to provoke
coronary artery spasm. Pts were divided into 2 groups according to results:
spasm group (60 pts) and non-spasm group (285 pts). We compared between
groups: 1) inflammatory markers including C-reactive protein (CRP), white
blood cells (WBC), polymorphonuclear neutrophils (PMN), monocytes (MO),
and lymphocytes (LY); 2) hemostasis markers including mean platelet volume
(MPV), platelet count, fibrinogen (FIB) and D-Dimers (DD); 3) traditional risk
factors for vascular disease, ie. hyperlipidemia, triglycerides (TG), total choles-
terol (TC), LDL and HDL cholesterol (LDL-C, HDL-C) and uric acid (UA).
Results Compared with females, more males with chest pain suffered spasm
during the provocation test (23.56% vs 11.11%, p<0.05). There was no significant
difference in serum levels of LDL-C, HDL-C, TG, TC, LY, MPV and FIB
between groups (p>0.05). Serum levels of CRP and blood counts of PMN and
MO were signicantly higher in the spasm group (P<0.05). Compared with
females, males had a higher frequency of a history of smoking (58.04% vs
46.78%, P<0.05). Logistic regression analysis showed that smoking, PMN and
MO counts were significantly and independently associated with coronary artery
spasm with odds ratios (OR) of 3.52 (1.79-6.90 95% CI, P=0.000), 1.21 (1.07-
1.46 95% CI, P=0.04) and 5.35 (1.37-21.07 95% CI, P=0.01), respectively.
Conclusions Inflammation may contribute to pathogenesis of coronary
artery spasm. Smoking, PMN count and MO count appear to be clinical risk
factors for coronary artery spasm. Conversely, spasm does not seem to be
associated with abnormalities in thrombogenesis.
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Aims: Recommendations on the use of antithrombotic agents, antihyperten-
sive drugs and statin for secondary prevention of coronary artery (CAD), isch-
emic cerebrovacular (CVD), and peripheral arterial (PAD) diseases are now well
established. However, there may be a gap between clinical practice and evi-
dence-based guidelines. We aimed to investigate the premorbid use of secondary
prevention medications in patients with recurrent cardiovascular events.
Methods and results: We prospectively recorded all patients with CVD and
CAD in Dijon, France from 2006 to 2010. Data about medical history and prior
use of treatments were collected. Mutivariate analyses were performed to identify
predictors of the use of medications in patients with previous cardiovascular dis-
ease. Among the 2126 patients included (1270 CVD and 856 CAD), 867 (40.8%)
had a history of cardiovascular diseases including 448 (51.7%) with prior CVD
only, 191 (22.0%) with prior CAD only, 68 (7.8%) with prior PAD only, and 160
(18.5%) with polyvascular disease. In these patients, 57.3% were on antithrom-
botic therapy, 61.2% were treated with antihypertensive drugs, 32.9% received
statins, and only 23.6% were on an optimal regimen, defined as the combination
of the three therapies. Compared with patients with previous CAD only, those
with previous CVD only were less likely to be receiving each of these treatments
or to receive an optimal regimen (OR=0.17, p<0.001).
Conclusion: This study highlighted the underuse of recommended sec-
ondary preventive therapies in current clinical practice. Underuse was partic-
ularly pronounced in patients with previous CVD. These findings may account
for the burden of recurrent events.
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Objective Platelet activation is present in atrial fibrillation (AF), but there is
some debate whether this is due to AF itself and/or to underlying cardiovascular
diseases. We aim to determine the association between a marker of platelet reac-
tivity (mean platelet volume (MPV)) and systemic inflammation (CRP) mea-
sured on admission, and new onset episode of AF in patients with MI.
Patients and methods Prospective cohort of 4994 consecutive patients
with AMI. Patients with paroxysmal or persistent AF were excluded.
Results 426 (8.5%) patients were diagnosed with a new onset of AF during
the in-hospital-stay (mean stay 3±2 days). These patients were older (75 vs 65,
p<0.001), predominantly male, and prevalence of hypertension and diabetes was
greater. Also less smoker were found among this group. Despite similar reper-
fusion strategies, clinical presentation with heart failure and increased heart rate
(HR) was more frequently found in patients with AF. Left ventricular ejection
fraction (LVEF) was significantly depressed in AF patients (47 vs. 55, p<0.001),
among with increased NT-proBNP, admission MPV (8.9 vs. 8.6, p<0.001) and
CRP (10.7 vs 5.7, p<0.001). Backward logistic regression analysis (model 1)
found that age [OR=1.04, 95%CI (1.031-1.050), p<0.001)], HR [OR=1.016,
95%CI (1.011-1.021), p<0.001)], LVEF [OR=0.979, 95%CI (0.970-0.987),
p<0.001)] and MPV [OR=1.182, 95%CI (1.064-1.312), p<0.001)] were inde-
pendent predictors of AF occurrence. A second backward regression analysis
(model 2= model 1+CRP) found that age [OR=1.036, 95%CI (1.026-1.046),
p<0.001)], HR [OR=1.013, 95%CI (1.008-1.018), p<0.001)], LVEF [OR=0.977,
95%CI (0.968-0.987), p<0.001)] and CRP [OR=1.003, 95%CI (1.001-1.005),
p=0.006)] were independent predictors of AF occurrence after MI.
Conclusions This study suggested that new onset of AF early after MI is
rather linked to inflammation induced by myocardial damage or the existing
atherosclerotic burden than platelet activation.
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